Genmab — Marts 2023
-
Godmorgen
-
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer https://www.sciencedirect.com/science/article/abs/pii/S1558767323000435 https://www.clinical-genitourinary-cancer.com/article/S1558-7673(23)00043-5/fulltext
-
Jan van de Winkel i særklasse i dansk børselite: Ejer Genmab-aktier for 1,6 mia. https://medwatch.dk/Mennesker/article15440176.ece
-
small new Ph2 trial Epcoritamab and Rituximab for First-line Follicular Lymphoma -by Dana-Farber Cancer Institute https://clinicaltrials.gov/ct2/show/NCT05783609
-
Huge growth in the EPCORE NHL-5
trial , from 132 to 394 participants, from 6 to 15 arms https://clinicaltrials.gov/ct2/history/NCT05283720?A=52&B=53&C=merged#StudyPageTop -
well, theoretically could be both lol. They are adding arms with another drug, CC-99282, which you don't do if you don't hope for improvement... They are also adding arms for FL and MCL separately which i think indicates treatment is sufficient to do that
-
En opgørelse viser, at JVDW er den erhvervsleder der suverent har flest aktier i sit eget selskab nemlig aktier for 1,5 Mia. min ommeregner kunne ikke klare opgaven, men med blyant og papir nåede jeg frem til mere end 5 millioner aktier hvis jeg ikke har regnet forkert.
-
this amivantamab trial also expanding from 260 to 390 patients, 4 to 6 arms
https://clinicaltrials.gov/ct2/history/NCT05498428?A=8&B=9&C=merged#StudyPageTop
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind